Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102)

Kazuhiro Nishikawa, Tsunehiro Takahashi, Hiromasa Takaishi, Akira Miki, Hirokazu Noshiro, Takaki Yoshikawa, Yasunori Nishida, Satoru Iwasa, Hiroto Miwa, Toshiki Masuishi, Narikazu Boku, Yasuhide Yamada, Yasuhiro Kodera, Kazuhiro Yoshida, Satoshi Morita, Junichi Sakamoto, Shigetoyo Saji, Yuukou Kitagawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Paclitaxel is a standard second-line gastric cancer treatment in Japan. Trastuzumab could be active as second-line chemotherapy for taxane/trastuzumab-naïve patients with epidermal growth factor 2 (HER2)-positive advanced gastric cancer. Patients aged ≥20 years with HER2-positive, previously treated (except for trastuzumab and taxane), unresectable or recurrent gastric adenocarcinoma underwent combined trastuzumab (first and subsequent doses of 8 and 6 mg kg−1, respectively, every 3 weeks) and paclitaxel (days 1, 8, 15, every 4 weeks) treatment. Study endpoints were best overall response, progression-free survival, overall survival, and safety. From September 2011 to March 2012, 47 Japanese patients were enrolled. Forty patients discontinued treatment after a median of 128.5 (range 4–486) days. Complete and partial responses were obtained in one and 16 patients (response rate of 37% [95% CI 23–52]), respectively. Median progression-free survival and overall survival were 5.1 (95% CI 3.8–6.5) and 17.1 (95% CI 13.5–18.6) months, respectively. Grade 3/4 adverse events were neutropenia (32.6%), leukopenia (17.4%), anemia (15.2%) and hypoalbuminemia (8.7%). There was no clinically significant cardiotoxicity or cumulative toxicity. Three (disturbed consciousness, pulmonary fibrosis, and rapid disease progression) grade 5 events occurred. In conclusion, trastuzumab combined with paclitaxel was well tolerated and was a promising regimen for patients with HER2-positive, previously treated, advanced or recurrent gastric cancer.

Original languageEnglish
Pages (from-to)188-196
Number of pages9
JournalInternational Journal of Cancer
Volume140
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Paclitaxel
Stomach Neoplasms
Safety
Disease-Free Survival
Hypoalbuminemia
Survival
Pulmonary Fibrosis
Leukopenia
Neutropenia
Consciousness
Epidermal Growth Factor
Disease Progression
Trastuzumab
taxane
Anemia
Stomach
Japan
Adenocarcinoma
Therapeutics
Drug Therapy

Keywords

  • human epidermal growth factor receptor
  • paclitaxel
  • recurrence
  • stomach neoplasms
  • trastuzumab

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). / Nishikawa, Kazuhiro; Takahashi, Tsunehiro; Takaishi, Hiromasa; Miki, Akira; Noshiro, Hirokazu; Yoshikawa, Takaki; Nishida, Yasunori; Iwasa, Satoru; Miwa, Hiroto; Masuishi, Toshiki; Boku, Narikazu; Yamada, Yasuhide; Kodera, Yasuhiro; Yoshida, Kazuhiro; Morita, Satoshi; Sakamoto, Junichi; Saji, Shigetoyo; Kitagawa, Yuukou.

In: International Journal of Cancer, Vol. 140, No. 1, 01.01.2017, p. 188-196.

Research output: Contribution to journalArticle

Nishikawa, K, Takahashi, T, Takaishi, H, Miki, A, Noshiro, H, Yoshikawa, T, Nishida, Y, Iwasa, S, Miwa, H, Masuishi, T, Boku, N, Yamada, Y, Kodera, Y, Yoshida, K, Morita, S, Sakamoto, J, Saji, S & Kitagawa, Y 2017, 'Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102)', International Journal of Cancer, vol. 140, no. 1, pp. 188-196. https://doi.org/10.1002/ijc.30383
Nishikawa, Kazuhiro ; Takahashi, Tsunehiro ; Takaishi, Hiromasa ; Miki, Akira ; Noshiro, Hirokazu ; Yoshikawa, Takaki ; Nishida, Yasunori ; Iwasa, Satoru ; Miwa, Hiroto ; Masuishi, Toshiki ; Boku, Narikazu ; Yamada, Yasuhide ; Kodera, Yasuhiro ; Yoshida, Kazuhiro ; Morita, Satoshi ; Sakamoto, Junichi ; Saji, Shigetoyo ; Kitagawa, Yuukou. / Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). In: International Journal of Cancer. 2017 ; Vol. 140, No. 1. pp. 188-196.
@article{59bf7873fb154f82a8e0533156936a39,
title = "Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-na{\"i}ve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102)",
abstract = "Paclitaxel is a standard second-line gastric cancer treatment in Japan. Trastuzumab could be active as second-line chemotherapy for taxane/trastuzumab-na{\"i}ve patients with epidermal growth factor 2 (HER2)-positive advanced gastric cancer. Patients aged ≥20 years with HER2-positive, previously treated (except for trastuzumab and taxane), unresectable or recurrent gastric adenocarcinoma underwent combined trastuzumab (first and subsequent doses of 8 and 6 mg kg−1, respectively, every 3 weeks) and paclitaxel (days 1, 8, 15, every 4 weeks) treatment. Study endpoints were best overall response, progression-free survival, overall survival, and safety. From September 2011 to March 2012, 47 Japanese patients were enrolled. Forty patients discontinued treatment after a median of 128.5 (range 4–486) days. Complete and partial responses were obtained in one and 16 patients (response rate of 37{\%} [95{\%} CI 23–52]), respectively. Median progression-free survival and overall survival were 5.1 (95{\%} CI 3.8–6.5) and 17.1 (95{\%} CI 13.5–18.6) months, respectively. Grade 3/4 adverse events were neutropenia (32.6{\%}), leukopenia (17.4{\%}), anemia (15.2{\%}) and hypoalbuminemia (8.7{\%}). There was no clinically significant cardiotoxicity or cumulative toxicity. Three (disturbed consciousness, pulmonary fibrosis, and rapid disease progression) grade 5 events occurred. In conclusion, trastuzumab combined with paclitaxel was well tolerated and was a promising regimen for patients with HER2-positive, previously treated, advanced or recurrent gastric cancer.",
keywords = "human epidermal growth factor receptor, paclitaxel, recurrence, stomach neoplasms, trastuzumab",
author = "Kazuhiro Nishikawa and Tsunehiro Takahashi and Hiromasa Takaishi and Akira Miki and Hirokazu Noshiro and Takaki Yoshikawa and Yasunori Nishida and Satoru Iwasa and Hiroto Miwa and Toshiki Masuishi and Narikazu Boku and Yasuhide Yamada and Yasuhiro Kodera and Kazuhiro Yoshida and Satoshi Morita and Junichi Sakamoto and Shigetoyo Saji and Yuukou Kitagawa",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/ijc.30383",
language = "English",
volume = "140",
pages = "188--196",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102)

AU - Nishikawa, Kazuhiro

AU - Takahashi, Tsunehiro

AU - Takaishi, Hiromasa

AU - Miki, Akira

AU - Noshiro, Hirokazu

AU - Yoshikawa, Takaki

AU - Nishida, Yasunori

AU - Iwasa, Satoru

AU - Miwa, Hiroto

AU - Masuishi, Toshiki

AU - Boku, Narikazu

AU - Yamada, Yasuhide

AU - Kodera, Yasuhiro

AU - Yoshida, Kazuhiro

AU - Morita, Satoshi

AU - Sakamoto, Junichi

AU - Saji, Shigetoyo

AU - Kitagawa, Yuukou

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Paclitaxel is a standard second-line gastric cancer treatment in Japan. Trastuzumab could be active as second-line chemotherapy for taxane/trastuzumab-naïve patients with epidermal growth factor 2 (HER2)-positive advanced gastric cancer. Patients aged ≥20 years with HER2-positive, previously treated (except for trastuzumab and taxane), unresectable or recurrent gastric adenocarcinoma underwent combined trastuzumab (first and subsequent doses of 8 and 6 mg kg−1, respectively, every 3 weeks) and paclitaxel (days 1, 8, 15, every 4 weeks) treatment. Study endpoints were best overall response, progression-free survival, overall survival, and safety. From September 2011 to March 2012, 47 Japanese patients were enrolled. Forty patients discontinued treatment after a median of 128.5 (range 4–486) days. Complete and partial responses were obtained in one and 16 patients (response rate of 37% [95% CI 23–52]), respectively. Median progression-free survival and overall survival were 5.1 (95% CI 3.8–6.5) and 17.1 (95% CI 13.5–18.6) months, respectively. Grade 3/4 adverse events were neutropenia (32.6%), leukopenia (17.4%), anemia (15.2%) and hypoalbuminemia (8.7%). There was no clinically significant cardiotoxicity or cumulative toxicity. Three (disturbed consciousness, pulmonary fibrosis, and rapid disease progression) grade 5 events occurred. In conclusion, trastuzumab combined with paclitaxel was well tolerated and was a promising regimen for patients with HER2-positive, previously treated, advanced or recurrent gastric cancer.

AB - Paclitaxel is a standard second-line gastric cancer treatment in Japan. Trastuzumab could be active as second-line chemotherapy for taxane/trastuzumab-naïve patients with epidermal growth factor 2 (HER2)-positive advanced gastric cancer. Patients aged ≥20 years with HER2-positive, previously treated (except for trastuzumab and taxane), unresectable or recurrent gastric adenocarcinoma underwent combined trastuzumab (first and subsequent doses of 8 and 6 mg kg−1, respectively, every 3 weeks) and paclitaxel (days 1, 8, 15, every 4 weeks) treatment. Study endpoints were best overall response, progression-free survival, overall survival, and safety. From September 2011 to March 2012, 47 Japanese patients were enrolled. Forty patients discontinued treatment after a median of 128.5 (range 4–486) days. Complete and partial responses were obtained in one and 16 patients (response rate of 37% [95% CI 23–52]), respectively. Median progression-free survival and overall survival were 5.1 (95% CI 3.8–6.5) and 17.1 (95% CI 13.5–18.6) months, respectively. Grade 3/4 adverse events were neutropenia (32.6%), leukopenia (17.4%), anemia (15.2%) and hypoalbuminemia (8.7%). There was no clinically significant cardiotoxicity or cumulative toxicity. Three (disturbed consciousness, pulmonary fibrosis, and rapid disease progression) grade 5 events occurred. In conclusion, trastuzumab combined with paclitaxel was well tolerated and was a promising regimen for patients with HER2-positive, previously treated, advanced or recurrent gastric cancer.

KW - human epidermal growth factor receptor

KW - paclitaxel

KW - recurrence

KW - stomach neoplasms

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84994406895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994406895&partnerID=8YFLogxK

U2 - 10.1002/ijc.30383

DO - 10.1002/ijc.30383

M3 - Article

VL - 140

SP - 188

EP - 196

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -